A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir

During the ongoing pandemic, providing treatment consisting of effective, low-cost oral antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling COVID-19. Although Paxlovid and molnupiravir have received emergency approval from the FDA, some side effect concerns...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yumin, Sun, Yuan, Xie, Yuanchao, Shang, Weijuan, Wang, Zhen, Jiang, Hualiang, Shen, Jingshan, Xiao, Gengfu, Zhang, Leike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514301/
https://www.ncbi.nlm.nih.gov/pubmed/37735468
http://dx.doi.org/10.1038/s41392-023-01587-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514301/
https://www.ncbi.nlm.nih.gov/pubmed/37735468
http://dx.doi.org/10.1038/s41392-023-01587-1

Ejemplares similares